PHIO 주가 차트
PHIO 수입
Phio Pharmaceuticals Corp
$1.11
3.73%
$0.04
오늘 기준:May 11, 11:32:52 GMT-4
뒤로
Phio Pharmaceuticals Corp (PHIO) 수입
최신 수익 결과: Q4 '25
보고됨: 2026-03-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
PHIO의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Phio Pharmaceuticals Corp PHIO의 지난 분기 매출 실적은 어땠나요?
Phio Pharmaceuticals Corp의 매출 추정치는 얼마인가요?
Phio Pharmaceuticals Corp의 수익 품질 점수는 얼마인가요?
Phio Pharmaceuticals Corp는 언제 수익을 보고하나요?
Phio Pharmaceuticals Corp의 예상 수익은 얼마인가요?
Phio Pharmaceuticals Corp은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.07
시가
$1.1
일일 범위
$1.08 - $1.11
52주 범위
$0.8127 - $4.18
거래량
84.4K
평균 거래량
2.6M
배당수익률
--
EPS(TTM)
-1.55
시가총액
$12.8M
PHIO란 무엇인가요?
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company is headquartered in King Of Prussia, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2012-05-10. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
